Pulmonary arterial hypertension and benfluorex: 5 case reports.

Abstract

Benfluorex, an amphetamine derivative, was marketed as an adjunctive drug for patients with hypertriglyceridemia or diabetes with overweight. We describe here 5 cases of pulmonary arterial hypertension (PAH) associated to a treatment with this drug and notified to the Midi-Pyrénées Pharmacovigilance Centre. All cases are women, exposed to benfluorex during at least 3 years. In most of cases, benfluorex was used off-licence, for overweight.

• Authors: Emmanuelle Bondon-Guitton, Grégoire Prévôt, Alain Didier, Jean-Louis Montastruc
• Journal: Therapie (Therapie) 2011 Mar-Apr Vol. 66 Issue 2 Pg. 135-8 ISSN: 0040-5957 [Print] France
• PMID: 21635861 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2011 Société Française de Pharmacologie et de Thérapeutique.

Chemical References

• Appetite Depressants
• Calcium Channel Blockers
• Diuretics
• Hypolipidemic Agents
• Fenfluramine
• benfluorex
• Furosemide
• Diltiazem
• Oxygen

Topics

• Adult
• Aged
• Appetite Depressants (adverse effects)
• Calcium Channel Blockers (therapeutic use)
• Diltiazem (therapeutic use)
• Diuretics (therapeutic use)
• Dyspnea (chemically induced)
• Familial Primary Pulmonary Hypertension
• Female
• Fenfluramine (adverse effects, analogs & derivatives)
• Furosemide (therapeutic use)
• Humans
• Hypertension, Pulmonary (chemically induced, therapy)
• Hypolipidemic Agents (adverse effects)
• Middle Aged
• Mitral Valve Insufficiency (complications, surgery)
• Obesity (complications, drug therapy)
• Oxygen (therapeutic use)
• Sleep Apnea Syndromes (complications)